Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
- Conditions
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 6
- Registration Number
- NCT00293371
- Locations
- 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2021-05-18
- Target Recruit Count
- 586
- Registration Number
- NCT00290667
- Locations
- 🇨🇿
University Hospital Brno, Brno, Czechia
🇫🇷Hopital Debrousse, Lyon, France
🇨🇿Charles University Hospital, Prague 5, Czechia
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
- Conditions
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 67
- Registration Number
- NCT00290498
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 612
- Registration Number
- NCT00288080
- Locations
- 🇺🇸
DeCesaris Cancer Institute at Anne Arundel Medical Center, Annapolis, Maryland, United States
🇺🇸St. Agnes Hospital Cancer Center, Baltimore, Maryland, United States
🇺🇸Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, United States
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma
- Conditions
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 65
- Registration Number
- NCT00284271
- Locations
- 🇩🇪
University of Cologne, Cologne, Germany
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT00282347
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
- First Posted Date
- 2006-01-18
- Last Posted Date
- 2013-12-19
- Target Recruit Count
- 150
- Registration Number
- NCT00278278
- Locations
- 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2006-01-18
- Last Posted Date
- 2021-03-10
- Target Recruit Count
- 700
- Registration Number
- NCT00278408
- Locations
- 🇩🇪
Virngrund-Klinik Ellwangen, Ellwangen, Germany
🇩🇪Klinikum Bayreuth, Bayreuth, Germany
🇩🇪University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-01-18
- Last Posted Date
- 2021-03-11
- Target Recruit Count
- 592
- Registration Number
- NCT00278421
- Locations
- 🇩🇪
Klinikum Lippe - Lemgo, Lemgo, Germany
🇩🇪Onkologische Schwerpunktpraxis, Wendlingen, Germany
🇩🇪Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany
The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 165
- Registration Number
- NCT00275535
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.